ETX Stock Overview
Engages in drug discovery research activities in the United Kingdom.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
e-therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.09 |
| 52 Week High | UK£0.24 |
| 52 Week Low | UK£0.08 |
| Beta | 0.43 |
| 1 Month Change | -28.00% |
| 3 Month Change | -41.18% |
| 1 Year Change | -29.27% |
| 3 Year Change | -65.78% |
| 5 Year Change | 332.69% |
| Change since IPO | -86.67% |
Recent News & Updates
Recent updates
e-therapeutics (LON:ETX) Is In A Good Position To Deliver On Growth Plans
Jan 05
We Think e-therapeutics (LON:ETX) Can Afford To Drive Business Growth
Sep 13e-therapeutics (LON:ETX) Is In A Good Position To Deliver On Growth Plans
Mar 27We Think e-therapeutics (LON:ETX) Can Afford To Drive Business Growth
Jul 07We're Not Worried About e-therapeutics' (LON:ETX) Cash Burn
Oct 28Have Insiders Been Buying e-therapeutics plc (LON:ETX) Shares?
Mar 21We Think e-therapeutics (LON:ETX) Can Afford To Drive Business Growth
Feb 14Could The e-therapeutics plc (LON:ETX) Ownership Structure Tell Us Something Useful?
Jan 10
Are Insiders Buying e-therapeutics plc (LON:ETX) Stock?
Dec 06Shareholder Returns
| ETX | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -4.3% | 1.0% | 0.2% |
| 1Y | -29.3% | -20.7% | 6.5% |
Return vs Industry: ETX underperformed the UK Biotechs industry which returned -23.5% over the past year.
Return vs Market: ETX underperformed the UK Market which returned 5.2% over the past year.
Price Volatility
| ETX volatility | |
|---|---|
| ETX Average Weekly Movement | 10.2% |
| Biotechs Industry Average Movement | 8.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.2% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: ETX's share price has been volatile over the past 3 months.
Volatility Over Time: ETX's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 34 | Ahmad Mortazavi | www.etherapeutics.co.uk |
e-therapeutics plc engages in drug discovery research activities in the United Kingdom. It offers HepNet, a proprietary, hepatocyte-specific, and computational biology platform that addresses key limitations of the biopharmaceutical industry, including extracting value from big data, addressing complex diseases, and improving translatability in research and development; and GalOmic, a RNA interference (RNAi) chemistry platform, which enables the generation of GalNAc-conjugated short interfering RNA drug candidates for hepatocyte-specific gene silencing through RNAi of any target gene identified by HepNet. The company was incorporated in 2001 and is based in London, the United Kingdom.
e-therapeutics plc Fundamentals Summary
| ETX fundamental statistics | |
|---|---|
| Market cap | UK£52.59m |
| Earnings (TTM) | -UK£10.06m |
| Revenue (TTM) | UK£340.00k |
154.7x
P/S Ratio-5.2x
P/E RatioIs ETX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ETX income statement (TTM) | |
|---|---|
| Revenue | UK£340.00k |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£340.00k |
| Other Expenses | UK£10.40m |
| Earnings | -UK£10.06m |
Last Reported Earnings
Jul 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.017 |
| Gross Margin | 100.00% |
| Net Profit Margin | -2,957.65% |
| Debt/Equity Ratio | 0% |
How did ETX perform over the long term?
See historical performance and comparison